| Literature DB >> 34051062 |
Abstract
Despite tremendous worldwide efforts, clinical trials assessing Alzheimer's disease (AD)-related therapeutics have been relentlessly unsuccessful. Hence, there is an urgent need to challenge old hypotheses with novel paradigms. An emerging concept is that the amyloid-beta (Aβ) peptide, which was until recently deemed a major player in the cause of AD, may instead modulate synaptic plasticity and protect against excitotoxicity. The link between Aβ-mediated synaptic plasticity and Aβ trafficking is central for understanding AD pathogenesis and remains a perplexing relationship. The crossover between Aβ pathological and physiological roles is subtle and remains controversial. Based on existing literature, as a signaling molecule, Aβ is proposed to modulate its own turnover and synaptic plasticity through what is currently believed to be the cause of AD: the transient formation of pore-like oligomers. A change of perspective regarding how Aβ pores exert a protective function will unavoidably revolutionize the entire field of anti-amyloid drug development.Entities:
Keywords: Alzheimer's disease; aging; beta-amyloid pore; calcium; cholesterol dyshomeostasis; endocytic trafficking; excitotoxicity; synaptic plasticity
Mesh:
Substances:
Year: 2021 PMID: 34051062 PMCID: PMC9290490 DOI: 10.1002/alz.12373
Source DB: PubMed Journal: Alzheimers Dement ISSN: 1552-5260 Impact factor: 16.655
FIGURE 1Schematic diagram of secretases cleavage of the precursor and derived products
FIGURE 2Proposed mechanisms for the physiological Aβ pore‐mediated regulation of synaptic activity (left panel), and the affected Aβ signaling associated with aging (right panel). Figure created with BioRender.com